Comparison of Etests and Vitek 2 {R }to broth microdilution for the susceptibility testing of Cryptococcus neoformans

Mahabeer Yesholata, Christina Catherine Chang, Dianithi Naidu, Afton A Dorasamy, Sharon Ruth Lewin, Thumbi Ndung'u, Mahomed-Yunus Suleman Moosa, Martyn A French, Koleka Mlisana, Yacoob Coovadia

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)


We determined the susceptibility of 102 clinical isolates Cryptococcus neoformans from Durban, South Africa, to amphotericin B, fluconazole, flucytosine, and voriconazole using broth microdilution (BMD) according to the Clinical and Laboratory Standards Institute M27-A3 document and compared these results with Etest and Vitek 2?. Essential agreement (EA) of Etest and Vitek 2? compared to BMD was determined. Low MICs that were below the epidemiological cutoff values of the 4 antifungal agents tested were demonstrated by all isolates. The EA of Etests for fluconazole, amphotericin, and voriconazole was 95.1 , 83.3 , and 91.2 , respectively, and for Vitek 2? EA for fluconazole, amphotericin, and flucytosine was 97.1 , 95.1 , and 97.1 , respectively. The Vitek 2? showed good agreement with BMD and is a suitable alternative. Etests demonstrated good EA for azoles only. Clinical cryptococcal isolates from Durban remain susceptible to current recommended antifungal therapy.
Original languageEnglish
Pages (from-to)294 - 298
Number of pages5
JournalDiagnostic Microbiology and Infectious Disease
Issue number4
Publication statusPublished - 2014

Cite this